Tango Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Tango Therapeutics

12/05/2025 15:17

Tango Therapeutics Inc TNGX.OQ reported a quarterly adjusted loss of 36 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -35 cents.  The mean expectation of seven analysts for the quarter was for a loss of 35 cents per share. Wall Street expected results to range from -38 cents to -31 cents per share.

Revenue fell 16.7% to $5.39 million from a year ago; analysts expected $6.69 million.

Tango Therapeutics Inc's reported EPS for the quarter was a loss of 36 cents​.

The company reported a quarterly loss of $39.88 million.

Tango Therapeutics Inc shares had fallen by 16.8% this quarter and lost 63.1% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 1.7% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."

Wall Street's median 12-month price target for Tango Therapeutics Inc is $10.00

This summary was machine generated from LSEG data May 12 at 02:17 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.35
-0.36
Missed
Dec. 31 2024
-0.34
-0.35
Missed
Sep. 30 2024
-0.37
-0.27
Beat
Jun. 30 2024
-0.34
-0.24
Beat